KR20220080139A - 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법 - Google Patents

인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법 Download PDF

Info

Publication number
KR20220080139A
KR20220080139A KR1020227015216A KR20227015216A KR20220080139A KR 20220080139 A KR20220080139 A KR 20220080139A KR 1020227015216 A KR1020227015216 A KR 1020227015216A KR 20227015216 A KR20227015216 A KR 20227015216A KR 20220080139 A KR20220080139 A KR 20220080139A
Authority
KR
South Korea
Prior art keywords
cancer
compound
cells
melanoma
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227015216A
Other languages
English (en)
Korean (ko)
Inventor
자로드 롱코르
Original Assignee
셀렉타 바이오사이언시스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀렉타 바이오사이언시스, 인코퍼레이티드 filed Critical 셀렉타 바이오사이언시스, 인코퍼레이티드
Publication of KR20220080139A publication Critical patent/KR20220080139A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227015216A 2019-10-10 2020-10-09 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법 Pending KR20220080139A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913571P 2019-10-10 2019-10-10
US62/913,571 2019-10-10
PCT/US2020/055121 WO2021072300A1 (en) 2019-10-10 2020-10-09 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Publications (1)

Publication Number Publication Date
KR20220080139A true KR20220080139A (ko) 2022-06-14

Family

ID=75436788

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015216A Pending KR20220080139A (ko) 2019-10-10 2020-10-09 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법

Country Status (11)

Country Link
US (1) US12496346B2 (https=)
EP (1) EP4041718A4 (https=)
JP (1) JP7631329B2 (https=)
KR (1) KR20220080139A (https=)
CN (1) CN114761389B (https=)
AU (1) AU2020361679B2 (https=)
BR (1) BR112022006739B1 (https=)
CA (1) CA3154192A1 (https=)
IL (1) IL291979B2 (https=)
MX (1) MX2022004341A (https=)
WO (1) WO2021072300A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095515A1 (en) 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
BR112022006739B1 (pt) 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
WO2025073824A1 (en) * 2023-10-03 2025-04-10 Aarhus Universitet Phospholipid conjugates and their uses

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965391A (en) 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE4132344A1 (de) 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DE4408011C1 (de) 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
CA2276284C (en) 1996-12-04 2006-10-10 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
ATE437657T1 (de) 2004-03-02 2009-08-15 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US7632644B2 (en) 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
EP1773408A2 (en) 2004-07-08 2007-04-18 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
MX2007007497A (es) 2004-12-20 2008-01-11 Cellectar Llc Analogos de fosfolipido eter para la deteccion y tratamiento del cancer.
UA99434C2 (ru) 2005-12-19 2012-08-27 Аетерна Центаріс Гмбх Применение производных алкилфосфолипидов со сниженной цитотоксичностью
US7893286B2 (en) 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
US8022235B2 (en) 2007-06-01 2011-09-20 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
US20100120727A1 (en) 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
US20100286510A1 (en) 2009-05-11 2010-11-11 Pinchuk Anatoly Use of fluorescent phospholipid ether compounds in biopsies
ES2549459T3 (es) 2009-05-11 2015-10-28 Cellectar, Inc. Compuestos de éter de fosfolípido fluorescentes, composiciones y procedimientos de uso
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
US7811548B1 (en) 2009-05-11 2010-10-12 Cellectar, Inc. Fluorescent phospholipid ether compounds and compositions
JP6092624B2 (ja) 2009-06-12 2017-03-08 セレクター，インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
WO2011031919A2 (en) 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
US20140255432A1 (en) * 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2014106826A2 (en) 2013-01-07 2014-07-10 Piramal Enterprises Limited Anthracycline analogue and uses thereof
FR3023290B1 (fr) 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
KR102508023B1 (ko) 2014-09-03 2023-03-10 이뮤노젠 아이엔씨 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
CA2968145C (en) 2014-11-17 2023-06-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
DK3888658T3 (da) 2015-11-25 2024-03-18 Effector Therapeutics Inc Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
WO2017214024A1 (en) * 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2017218702A1 (en) 2016-06-14 2017-12-21 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
US11286281B2 (en) 2017-05-10 2022-03-29 Zealand Pharma A/S Homodetic cyclic peptides targeting alpha-4-beta-7 integrin
US11167050B2 (en) 2017-09-26 2021-11-09 National University Corporation Chiba University Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
CA3095515A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
SG11202009990UA (en) 2018-04-16 2020-11-27 Nihon Mediphysics Co Ltd Modified antibody and radioactive metal-labelled antibody
NZ786360A (en) * 2019-09-12 2025-12-19 Cellectar Biosciences Inc Phospholipid ether conjugates as cancer-targeting drug vehicles
BR112022006739B1 (pt) 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer

Also Published As

Publication number Publication date
JP2022551495A (ja) 2022-12-09
BR112022006739A2 (pt) 2022-06-28
BR112022006739B1 (pt) 2024-01-23
IL291979B2 (en) 2025-12-01
AU2020361679A1 (en) 2022-04-28
EP4041718A4 (en) 2023-12-20
CN114761389A (zh) 2022-07-15
EP4041718A1 (en) 2022-08-17
IL291979B1 (en) 2025-08-01
US20240325545A1 (en) 2024-10-03
CN114761389B (zh) 2025-02-07
MX2022004341A (es) 2022-08-10
JP7631329B2 (ja) 2025-02-18
WO2021072300A1 (en) 2021-04-15
US12496346B2 (en) 2025-12-16
AU2020361679B2 (en) 2026-03-19
CA3154192A1 (en) 2021-04-15
IL291979A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
KR101915452B1 (ko) 백금 화합물, 조성물 및 이의 용도
CN113896731A (zh) 细胞毒性苯并二氮杂䓬衍生物
CN107708702A (zh) 磷脂醚类似物作为靶向癌症的药物载体
KR20220080139A (ko) 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
CN108368143B (zh) 用于癌症疗法的单马来酰亚胺官能化的铂化合物
KR20220062363A (ko) 암 표적성 약물 전달체로서의 인지질 에테르 접합체
US20260042773A1 (en) Novel camptothecin analogs and immunoconjugates thereof
KR102821508B1 (ko) 인지질-플라베글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
WO2017180723A1 (en) Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
EA047198B1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для нацеленной противораковой терапии
WO2011009059A2 (en) Method of treating or preventing cancer
HK40043232B (zh) 磷脂-flavagline缀合物及将其用於靶向癌症治疗的方法
EA053296B1 (ru) Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак
AU2023278382A1 (en) Camptothecin prodrug and pharmaceutical composition thereof
CN121358743A (zh) 用于治疗或预防癌症的喜树碱衍生物及其抗体药物偶联物
HK40043232A (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701